+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Desmopressin Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Desmopressin Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Desmopressin Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6083053
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Desmopressin Market grew from USD 1.30 billion in 2024 to USD 1.40 billion in 2025. It is expected to continue growing at a CAGR of 7.09%, reaching USD 1.97 billion by 2030.

Desmopressin has emerged as a cornerstone therapy in managing a range of disorders from central diabetes insipidus to primary nocturnal enuresis. As an analog of vasopressin, its enhanced stability and targeted activity profile have driven broader adoption across clinical settings. Recent advancements in formulation technologies have expanded the avenues of administration beyond traditional oral tablets to include intranasal sprays and injectable presentations, offering clinicians and patients greater flexibility. Furthermore, evolving patient demographics and a growing emphasis on personalized medicine are shaping how stakeholders approach clinical development, regulatory approval, and market access for desmopressin products. In this context, synthesizing the multifaceted shifts in regulation, supply chain dynamics, and competitive positioning becomes pivotal for decision-makers seeking to navigate the complexities of this market segment with confidence and clarity.

Transformative Shifts Reshaping the Desmopressin Landscape

Over the past five years, the desmopressin landscape has undergone transformative shifts driven by technological, regulatory, and patient-centric pressures. Innovations in drug delivery have propelled the rise of prefilled syringes and vials under the injectable category, alongside aqueous and non-aqueous intranasal sprays that offer rapid onset for nocturia and enuresis. Concurrently, extended-release tablet formulations have gained traction for ensuring steady plasma levels in endocrine applications. Regulatory agencies have responded to safety and efficacy demands by streamlining approval pathways for novel formulations while tightening post-market surveillance, especially for at-risk populations.

Market consolidation among specialty pharma providers and emerging collaborations between biotechnology firms and contract manufacturing organizations have accelerated time to market for next-generation desmopressin products. Patient advocacy groups have also exerted greater influence, pushing for noninvasive administration options and transparent pricing models. As a result, strategic alliances now prioritize co-development agreements and licensing partnerships that blend novel excipient technologies with robust commercial networks, setting the stage for a new era of product differentiation and value-based contracting.

Cumulative Impact of United States Tariffs in 2025

United States tariffs introduced in early 2025 have produced a cumulative impact across raw material procurement, manufacturing costs, and distribution margins. API suppliers, many of which rely on intermediates sourced from overseas, have faced increased input costs that are now being negotiated through long-term supply agreements and forward pricing contracts. Domestic manufacturers have partly mitigated these pressures by reshoring key synthesis steps, investing in continuous flow chemistry, and partnering with specialty chemical producers to secure tariff-exempt materials.

Distribution channels have likewise adapted: hospitals and clinics are absorbing a portion of the tariff-induced price increases by renegotiating procurement contracts, while homecare suppliers are leveraging direct-to-patient logistics to maintain competitive pricing. Insurance payers and pharmacy benefit managers have responded by tightening formulary access for premium intranasal and injectable presentations, favoring immediate-release oral formulations when clinically appropriate. These tariff-driven dynamics underscore the importance of supply chain resilience and strategic sourcing in protecting profit margins and ensuring uninterrupted patient access.

Key Insights Across Product, Application, End User, and Other Segments

Segmenting the desmopressin market across product type, application, end user, age group, route of administration, and disorder type reveals nuanced growth drivers and areas for innovation. When examined by product type, the injectable segment-including both prefilled syringes and vials-continues to command premium positioning in hospital and surgical use thanks to its precise dosing and sterile delivery, while the intranasal spray modality-split into aqueous spray for rapid mucosal absorption and non-aqueous spray for extended residence time-addresses both nocturia and central diabetes insipidus. Tablets, divided into extended-release systems for sustained hormone control and immediate-release forms for acute symptom relief, capture the broad outpatient population.

From an application perspective, bedwetting remains a core indication, particularly in primary nocturnal enuresis, complemented by secondary nocturnal enuresis in neurologically complex cases. Central and nephrogenic diabetes insipidus continue to drive demand for precise sodium and fluid homeostasis, whereas benign prostatic hyperplasia-related nocturia and sleep apnea-related nocturia represent emerging off-label opportunities. Surgical use in hemophilia A and von Willebrand disease underscores desmopressin’s utility in hemostatic management.

End users span homecare settings-where online and retail pharmacy distribution models are gaining share-through to general and specialized hospital clinics that prioritize injectable and intranasal options. Academic research institutes are exploring novel analogs and delivery platforms, while clinical research centers are spearheading pivotal trials for next-generation formulations.

Age group segmentation highlights adolescents, covering pre-teens and teens, as a priority for enuresis management, adults-including middle-aged and young adults-for widespread endocrine and nocturia applications, geriatric patients-active seniors and the elderly-for complex comorbidity management, and pediatric patients-children and toddlers-requiring tailored dosing and safety profiles.

In terms of route of administration, intravenous bolus and drip methods remain essential for perioperative hemostasis, nasal delivery via drops and sprays addresses outpatient convenience, and oral liquid and solid forms support chronic disorder management. Finally, distinguishing between chronic endocrine and pituitary disorders versus transient drug-induced and trauma-related conditions clarifies where long-term therapy investments or short-term utilization cycles will dominate.

Regional Evolution Driving Global Desmopressin Adoption

Regional dynamics illustrate that the Americas continue to lead in overall desmopressin revenue, driven by robust clinical adoption in both hospital and homecare settings, a mature insurance framework, and ongoing research collaborations between industry and academic institutions. Meanwhile, Europe, Middle East & Africa present diverse regulatory landscapes where market entry relies on navigating both the European Medicines Agency’s centralized procedures and localized national health technology assessments, with growing demand for cost-effective intranasal formulations in underserved markets. Asia-Pacific stands out for its accelerating clinical trial activity in China, Japan, and India, the expansion of private healthcare infrastructure, and rising patient awareness, which collectively fuel demand for oral extended-release tablets and novel nasal sprays. These regional variations underscore the need for tailored market access strategies and flexible supply chain models to meet distinct regulatory, reimbursement, and patient preference profiles.

Competitive Landscape and Leading Desmopressin Manufacturers

An increasingly competitive landscape features a mix of established pharma giants, specialty manufacturers, and emerging biotechs. AA Pharma Inc. and Amring Pharmaceuticals Inc. continue to leverage cost-competitiveness and robust generic pipelines, while Antares Pharma, Inc. by Halozyme, Inc. and Apotex Inc. push formulation innovations in intranasal delivery. Avadel Pharmaceuticals PLC and Bachem AG focus on peptide synthesis expertise, underpinning high-purity APIs. BluePoint Laboratories and CSC Pharmaceuticals International have carved niche positions in contract manufacturing, supporting both large-scale production and small-batch clinical supplies.

Major integrators such as Dr. Reddy’s Laboratories Ltd. and Ferring Pharmaceuticals lead in regulatory filings and global distribution networks, with Glenmark Pharmaceuticals Limited and Pfizer Inc. enhancing their portfolios through strategic acquisitions and licensing deals. Horizon NJ Health by Horizon Blue Cross Blue Shield of New Jersey exemplifies payer-provider collaboration on value-based reimbursement models for high-impact therapeutic areas. Specialty players like KVR Pharmaceuticals and Manus Aktteva Biopharma LLP are advancing next-generation analogs, while Midas Pharma GmbH and NorthStar Rx LLC excel in niche delivery formats. Ralington Pharma LLP, Saintroy Lifescience, and Sanofi S.A. leverage global marketing reach, and Sava Healthcare Limited and Sun Pharmaceutical Industries Limited maintain strong generics presence. Teva Pharmaceutical Industries Ltd. and VIVAN Life Sciences Pvt. Limited round out the field with diversified portfolios and emerging pipeline assets. Collectively, these companies are reshaping competitive positioning by integrating R&D investments with agile manufacturing capacities and differentiated market access strategies.

Actionable Strategies for Industry Leaders in Desmopressin Sector

Industry leaders should prioritize strengthening supply chain resilience by diversifying API sourcing and investing in continuous manufacturing technologies to mitigate geopolitical and tariff risks. Additionally, accelerating product differentiation through novel delivery platforms-such as mucoadhesive nasal sprays and microfluidic injectable cartridges-will help capture premium segments. Collaborating with payers on outcome-based contracts, particularly in nocturia and enuresis indications, can unlock new reimbursement pathways and enhance patient affordability. Furthermore, expanding direct-to-patient digital engagement tools for tracking adherence and outcomes will reinforce patient loyalty and generate real-world evidence. Finally, strategic alliances with academic and clinical research centers should focus on emerging indications, including sleep apnea-related nocturia and trauma-induced transient disorders, to build robust clinical data packages that support label expansions.

Conclusion: Navigating the Future of Desmopressin

As the desmopressin market continues to evolve, success will hinge on integrating innovative delivery technologies, dynamic pricing strategies, and collaborative research models. By aligning R&D investments with patient needs and regulatory trends, stakeholders can drive sustainable growth and reinforce desmopressin’s role as a versatile therapeutic agent. Building agile supply chains and forging payer partnerships will enable efficient market access, while deepening clinical evidence across novel applications will create new demand drivers. In this rapidly shifting environment, a proactive, data-driven approach will be essential for capturing opportunities and navigating challenges.

Market Segmentation & Coverage

This research report categorizes the Desmopressin Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Injectable
    • Prefilled Syringes
    • Vials
  • Intranasal Spray
    • Aqueous Spray
    • Non-Aqueous Spray
  • Tablets
    • Extended Release
    • Immediate Release
  • Bedwetting
    • Primary Nocturnal Enuresis
    • Secondary Nocturnal Enuresis
  • Diabetes Insipidus
    • Central Diabetes Insipidus
    • Nephrogenic Diabetes Insipidus
  • Nocturia
    • Benign Prostatic Hyperplasia (BPH) Related
    • Sleep Apnea Related
  • Surgical Use
    • Hemophilia A
    • Von Willebrand Disease
  • Homecare Settings
    • Online Pharmacy Distribution
    • Retail Pharmacy Distribution
  • Hospitals
    • General Hospitals
    • Specialized Clinics
  • Research Institutes
    • Academic Research
    • Clinical Research
  • Adolescents
    • Pre-Teens
    • Teens
  • Adults
    • Middle Age
    • Young Adults
  • Geriatric Patients
    • Active Seniors
    • Elderly
  • Pediatric Patients
    • Children
    • Toddlers
  • Intravenous
    • Bolus
    • Drip
  • Nasal
    • Drops
    • Sprays
  • Oral
    • Liquid Form
    • Solid Form
  • Chronic Disorders
    • Endocrine Disorders
    • Pituitary Disorders
  • Transient Disorders
    • Drug-Induced
    • Trauma Related

This research report categorizes the Desmopressin Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Desmopressin Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AA Pharma Inc.
  • Amring Pharmaceuticals Inc.
  • Antares Pharma, Inc. by Halozyme, Inc.
  • Apotex Inc.
  • Avadel Pharmaceuticals PLC
  • Bachem AG
  • BluePoint Laboratories
  • CSC Pharmaceuticals International
  • Dr. Reddy's Laboratories Ltd.
  • Enomark
  • Ferring Pharmaceuticals
  • Glenmark Pharmaceuticals Limited
  • Horizon NJ Health by Horizon Blue Cross Blue Shield of New Jersey
  • KVR Pharmaceuticals
  • Manus Aktteva Biopharma LLP
  • Midas Pharma GmbH
  • NorthStar Rx LLC
  • Pfizer Inc.
  • Ralington Pharma LLP
  • Saintroy Lifescience
  • Sanofi S.A.
  • Sava Healthcare Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • VIVAN Life Sciences Pvt. Limited

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Desmopressin Market, by Product Type
8.1. Introduction
8.2. Injectable
8.2.1. Prefilled Syringes
8.2.2. Vials
8.3. Intranasal Spray
8.3.1. Aqueous Spray
8.3.2. Non-Aqueous Spray
8.4. Tablets
8.4.1. Extended Release
8.4.2. Immediate Release
9. Desmopressin Market, by Application
9.1. Introduction
9.2. Bedwetting
9.2.1. Primary Nocturnal Enuresis
9.2.2. Secondary Nocturnal Enuresis
9.3. Diabetes Insipidus
9.3.1. Central Diabetes Insipidus
9.3.2. Nephrogenic Diabetes Insipidus
9.4. Nocturia
9.4.1. Benign Prostatic Hyperplasia (BPH) Related
9.4.2. Sleep Apnea Related
9.5. Surgical Use
9.5.1. Hemophilia A
9.5.2. Von Willebrand Disease
10. Desmopressin Market, by End User
10.1. Introduction
10.2. Homecare Settings
10.2.1. Online Pharmacy Distribution
10.2.2. Retail Pharmacy Distribution
10.3. Hospitals
10.3.1. General Hospitals
10.3.2. Specialized Clinics
10.4. Research Institutes
10.4.1. Academic Research
10.4.2. Clinical Research
11. Desmopressin Market, by Age Group
11.1. Introduction
11.2. Adolescents
11.2.1. Pre-Teens
11.2.2. Teens
11.3. Adults
11.3.1. Middle Age
11.3.2. Young Adults
11.4. Geriatric Patients
11.4.1. Active Seniors
11.4.2. Elderly
11.5. Pediatric Patients
11.5.1. Children
11.5.2. Toddlers
12. Desmopressin Market, by Route Of Administration
12.1. Introduction
12.2. Intravenous
12.2.1. Bolus
12.2.2. Drip
12.3. Nasal
12.3.1. Drops
12.3.2. Sprays
12.4. Oral
12.4.1. Liquid Form
12.4.2. Solid Form
13. Desmopressin Market, by Disorder Type
13.1. Introduction
13.2. Chronic Disorders
13.2.1. Endocrine Disorders
13.2.2. Pituitary Disorders
13.3. Transient Disorders
13.3.1. Drug-Induced
13.3.2. Trauma Related
14. Americas Desmopressin Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Desmopressin Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Desmopressin Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AA Pharma Inc.
17.3.2. Amring Pharmaceuticals Inc.
17.3.3. Antares Pharma, Inc. by Halozyme, Inc.
17.3.4. Apotex Inc.
17.3.5. Avadel Pharmaceuticals PLC
17.3.6. Bachem AG
17.3.7. BluePoint Laboratories
17.3.8. CSC Pharmaceuticals International
17.3.9. Dr. Reddy's Laboratories Ltd.
17.3.10. Enomark
17.3.11. Ferring Pharmaceuticals
17.3.12. Glenmark Pharmaceuticals Limited
17.3.13. Horizon NJ Health by Horizon Blue Cross Blue Shield of New Jersey
17.3.14. KVR Pharmaceuticals
17.3.15. Manus Aktteva Biopharma LLP
17.3.16. Midas Pharma GmbH
17.3.17. NorthStar Rx LLC
17.3.18. Pfizer Inc.
17.3.19. Ralington Pharma LLP
17.3.20. Saintroy Lifescience
17.3.21. Sanofi S.A.
17.3.22. Sava Healthcare Limited
17.3.23. Sun Pharmaceutical Industries Limited
17.3.24. Teva Pharmaceutical Industries Ltd.
17.3.25. VIVAN Life Sciences Pvt. Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. DESMOPRESSIN MARKET MULTI-CURRENCY
FIGURE 2. DESMOPRESSIN MARKET MULTI-LANGUAGE
FIGURE 3. DESMOPRESSIN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DESMOPRESSIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DESMOPRESSIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DESMOPRESSIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DESMOPRESSIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DESMOPRESSIN MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DESMOPRESSIN MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DESMOPRESSIN MARKET SIZE, BY DISORDER TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DESMOPRESSIN MARKET SIZE, BY DISORDER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES DESMOPRESSIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES DESMOPRESSIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. DESMOPRESSIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. DESMOPRESSIN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DESMOPRESSIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DESMOPRESSIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DESMOPRESSIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DESMOPRESSIN MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DESMOPRESSIN MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DESMOPRESSIN MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DESMOPRESSIN MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DESMOPRESSIN MARKET SIZE, BY AQUEOUS SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DESMOPRESSIN MARKET SIZE, BY NON-AQUEOUS SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DESMOPRESSIN MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DESMOPRESSIN MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DESMOPRESSIN MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DESMOPRESSIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DESMOPRESSIN MARKET SIZE, BY BEDWETTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DESMOPRESSIN MARKET SIZE, BY PRIMARY NOCTURNAL ENURESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DESMOPRESSIN MARKET SIZE, BY SECONDARY NOCTURNAL ENURESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DESMOPRESSIN MARKET SIZE, BY BEDWETTING, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DESMOPRESSIN MARKET SIZE, BY DIABETES INSIPIDUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DESMOPRESSIN MARKET SIZE, BY CENTRAL DIABETES INSIPIDUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DESMOPRESSIN MARKET SIZE, BY NEPHROGENIC DIABETES INSIPIDUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DESMOPRESSIN MARKET SIZE, BY DIABETES INSIPIDUS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DESMOPRESSIN MARKET SIZE, BY NOCTURIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DESMOPRESSIN MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA (BPH) RELATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DESMOPRESSIN MARKET SIZE, BY SLEEP APNEA RELATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DESMOPRESSIN MARKET SIZE, BY NOCTURIA, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DESMOPRESSIN MARKET SIZE, BY SURGICAL USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DESMOPRESSIN MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DESMOPRESSIN MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DESMOPRESSIN MARKET SIZE, BY SURGICAL USE, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DESMOPRESSIN MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DESMOPRESSIN MARKET SIZE, BY ONLINE PHARMACY DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DESMOPRESSIN MARKET SIZE, BY RETAIL PHARMACY DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DESMOPRESSIN MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DESMOPRESSIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DESMOPRESSIN MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DESMOPRESSIN MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DESMOPRESSIN MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DESMOPRESSIN MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DESMOPRESSIN MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DESMOPRESSIN MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DESMOPRESSIN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DESMOPRESSIN MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DESMOPRESSIN MARKET SIZE, BY PRE-TEENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DESMOPRESSIN MARKET SIZE, BY TEENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DESMOPRESSIN MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DESMOPRESSIN MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DESMOPRESSIN MARKET SIZE, BY MIDDLE AGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DESMOPRESSIN MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DESMOPRESSIN MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DESMOPRESSIN MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DESMOPRESSIN MARKET SIZE, BY ACTIVE SENIORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DESMOPRESSIN MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DESMOPRESSIN MARKET SIZE, BY GERIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DESMOPRESSIN MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DESMOPRESSIN MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DESMOPRESSIN MARKET SIZE, BY TODDLERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DESMOPRESSIN MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL DESMOPRESSIN MARKET SIZE, BY BOLUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL DESMOPRESSIN MARKET SIZE, BY DRIP, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL DESMOPRESSIN MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL DESMOPRESSIN MARKET SIZE, BY DROPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL DESMOPRESSIN MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL DESMOPRESSIN MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL DESMOPRESSIN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL DESMOPRESSIN MARKET SIZE, BY LIQUID FORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL DESMOPRESSIN MARKET SIZE, BY SOLID FORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL DESMOPRESSIN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL DESMOPRESSIN MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL DESMOPRESSIN MARKET SIZE, BY CHRONIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL DESMOPRESSIN MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL DESMOPRESSIN MARKET SIZE, BY PITUITARY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL DESMOPRESSIN MARKET SIZE, BY CHRONIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL DESMOPRESSIN MARKET SIZE, BY TRANSIENT DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL DESMOPRESSIN MARKET SIZE, BY DRUG-INDUCED, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL DESMOPRESSIN MARKET SIZE, BY TRAUMA RELATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL DESMOPRESSIN MARKET SIZE, BY TRANSIENT DISORDERS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS DESMOPRESSIN MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS DESMOPRESSIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS DESMOPRESSIN MARKET SIZE, BY BEDWETTING, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS DESMOPRESSIN MARKET SIZE, BY DIABETES INSIPIDUS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS DESMOPRESSIN MARKET SIZE, BY NOCTURIA, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS DESMOPRESSIN MARKET SIZE, BY SURGICAL USE, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS DESMOPRESSIN MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS DESMOPRESSIN MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS DESMOPRESSIN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS DESMOPRESSIN MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS DESMOPRESSIN MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS DESMOPRESSIN MARKET SIZE, BY GERIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS DESMOPRESSIN MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS DESMOPRESSIN MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS DESMOPRESSIN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS DESMOPRESSIN MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS DESMOPRESSIN MARKET SIZE, BY CHRONIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS DESMOPRESSIN MARKET SIZE, BY TRANSIENT DISORDERS, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA DESMOPRESSIN MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA DESMOPRESSIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA DESMOPRESSIN MARKET SIZE, BY BEDWETTING, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA DESMOPRESSIN MARKET SIZE, BY DIABETES INSIPIDUS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA DESMOPRESSIN MARKET SIZE, BY NOCTURIA, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA DESMOPRESSIN MARKET SIZE, BY SURGICAL USE, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA DESMOPRESSIN MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA DESMOPRESSIN MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA DESMOPRESSIN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA DESMOPRESSIN MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA DESMOPRESSIN MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA DESMOPRESSIN MARKET SIZE, BY GERIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA DESMOPRESSIN MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA DESMOPRESSIN MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA DESMOPRESSIN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA DESMOPRESSIN MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA DESMOPRESSIN MARKET SIZE, BY CHRONIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA DESMOPRESSIN MARKET SIZE, BY TRANSIENT DISORDERS, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL DESMOPRESSIN MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL DESMOPRESSIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL DESMOPRESSIN MARKET SIZE, BY BEDWETTING, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL DESMOPRESSIN MARKET SIZE, BY DIABETES INSIPIDUS, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL DESMOPRESSIN MARKET SIZE, BY NOCTURIA, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL DESMOPRESSIN MARKET SIZE, BY SURGICAL USE, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL DESMOPRESSIN MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL DESMOPRESSIN MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL DESMOPRESSIN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL DESMOPRESSIN MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL DESMOPRESSIN MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL DESMOPRESSIN MARKET SIZE, BY GERIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL DESMOPRESSIN MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL DESMOPRESSIN MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL DESMOPRESSIN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL DESMOPRESSIN MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL DESMOPRESSIN MARKET SIZE, BY CHRONIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL DESMOPRESSIN MARKET SIZE, BY TRANSIENT DISORDERS, 2018-2030 (USD MILLION)
TABLE 164. CANADA DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 165. CANADA DESMOPRESSIN MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 166. CANADA DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 167. CANADA DESMOPRESSIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 168. CANADA DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. CANADA DESMOPRESSIN MARKET SIZE, BY BEDWETTING, 2018-2030 (USD MILLION)
TABLE 170. CANADA DESMOPRESSIN MARKET SIZE, BY DIABETES INSIPIDUS, 2018-2030 (USD MILLION)
TABLE 171. CANADA DESMOPRESSIN MARKET SIZE, BY NOCTURIA, 2018-2030 (USD MILLION)
TABLE 172. CANADA DESMOPRESSIN MARKET SIZE, BY SURGICAL USE, 2018-2030 (USD MILLION)
TABLE 173. CANADA DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. CANADA DESMOPRESSIN MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 175. CANADA DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 176. CANADA DESMOPRESSIN MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 177. CANADA DESMOPRESSIN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 178. CANADA DESMOPRESSIN MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 179. CANADA DESMOPRESSIN MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 180. CANADA DESMOPRESSIN MARKET SIZE, BY GERIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 181. CANADA DESMOPRESSIN MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 182. CANADA DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. CANADA DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 184. CANADA DESMOPRESSIN MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 185. CANADA DESMOPRESSIN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 186. CANADA DESMOPRESSIN MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
TABLE 187. CANADA DESMOPRESSIN MARKET SIZE, BY CHRONIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 188. CANADA DESMOPRESSIN MARKET SIZE, BY TRANSIENT DISORDERS, 2018-2030 (USD MILLION)
TABLE 189. MEXICO DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. MEXICO DESMOPRESSIN MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 191. MEXICO DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 192. MEXICO DESMOPRESSIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 193. MEXICO DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 194. MEXICO DESMOPRESSIN MARKET SIZE, BY BEDWETTING, 2018-2030 (USD MILLION)
TABLE 195. MEXICO DESMOPRESSIN MARKET SIZE, BY DIABETES INSIPIDUS, 2018-2030 (USD MILLION)
TABLE 196. MEXICO DESMOPRESSIN MARKET SIZE, BY NOCTURIA, 2018-2030 (USD MILLION)
TABLE 197. MEXICO DESMOPRESSIN MARKET SIZE, BY SURGICAL USE, 2018-2030 (USD MILLION)
TABLE 198. MEXICO DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. MEXICO DESMOPRESSIN MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 200. MEXICO DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 201. MEXICO DESMOPRESSIN MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 202. MEXICO DESMOPRESSIN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 203. MEXICO DESMOPRESSIN MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 204. MEXICO DESMOPRESSIN MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 205. MEXICO DESMOPRESSIN MARKET SIZE, BY GERIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 206. MEXICO DESMOPRESSIN MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 207. MEXICO DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. MEXICO DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 209. MEXICO DESMOPRESSIN MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 210. MEXICO DESMOPRESSIN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 211. MEXICO DESMOPRESSIN MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
TABLE 212. MEXICO DESMOPRESSIN MARKET SIZE, BY CHRONIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 213. MEXICO DESMOPRESSIN MARKET SIZE, BY TRANSIENT DISORDERS, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES DESMOPRESSIN MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 217. UNITED STATES DESMOPRESSIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 218. UNITED STATES DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. UNITED STATES DESMOPRESSIN MARKET SIZE, BY BEDWETTING, 2018-2030 (USD MILLION)
TABLE 220. UNITED STATES DESMOPRESSIN MARKET SIZE, BY DIABETES INSIPIDUS, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES DESMOPRESSIN MARKET SIZE, BY NOCTURIA, 2018-2030 (USD MILLION)
TABLE 222. UNITED STATES DESMOPRESSIN MARKET SIZE, BY SURGICAL USE, 2018-2030 (USD MILLION)
TABLE 223. UNITED STATES DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. UNITED STATES DESMOPRESSIN MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 225. UNITED STATES DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 226. UNITED STATES DESMOPRESSIN MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 227. UNITED STATES DESMOPRESSIN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 228. UNITED STATES DESMOPRESSIN MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 229. UNITED STATES DESMOPRESSIN MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 230. UNITED STATES DESMOPRESSIN MARKET SIZE, BY GERIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 231. UNITED STATES DESMOPRESSIN MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 232. UNITED STATES DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. UNITED STATES DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 234. UNITED STATES DESMOPRESSIN MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 235. UNITED STATES DESMOPRESSIN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 236. UNITED STATES DESMOPRESSIN MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
TABLE 237. UNITED STATES DESMOPRESSIN MARKET SIZE, BY CHRONIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 238. UNITED STATES DESMOPRESSIN MARKET SIZE, BY TRANSIENT DISORDERS, 2018-2030 (USD MILLION)
TABLE 239. UNITED STATES DESMOPRESSIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY BEDWETTING, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY DIABETES INSIPIDUS, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY NOCTURIA, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY SURGICAL USE, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 251. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 252. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 253. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 254. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 255. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 256. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY GERIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 257. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 258. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY CHRONIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY TRANSIENT DISORDERS, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC DESMOPRESSIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY BEDWETTING, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY DIABETES INSIPIDUS, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY NOCTURIA, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY SURGICAL USE, 2018-2030 (USD MILLION)
TABLE 275. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 277. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 278. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 279. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 280. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 281. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 282. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY GERIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 283. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 284. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 286. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 287. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 288. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
TABLE 289. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY CHRONIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 290. AUSTRALIA DESMOPRESSIN MARKET SIZE, BY TRANSIENT DISORDERS, 2018-2030 (USD MILLION)
TABLE 291. CHINA DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 292. CHINA DESMOPRESSIN MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 293. CHINA DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 294. CHINA DESMOPRESSIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 295. CHINA DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 296. CHINA DESMOPRESSIN MARKET SIZE, BY BEDWETTING, 2018-2030 (USD MILLION)
TABLE 297. CHINA DESMOPRESSIN MARKET SIZE, BY DIABETES INSIPIDUS, 2018-2030 (USD MILLION)
TABLE 298. CHINA DESMOPRESSIN MARKET SIZE, BY NOCTURIA, 2018-2030 (USD MILLION)
TABLE 299. CHINA DESMOPRESSIN MARKET SIZE, BY SURGICAL USE, 2018-2030 (USD MILLION)
TABLE 300. CHINA DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. CHINA DESMOPRESSIN MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 302. CHINA DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 303. CHINA DESMOPRESSIN MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 304. CHINA DESMOPRESSIN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 305. CHINA DESMOPRESSIN MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 306. CHINA DESMOPRESSIN MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 307. CHINA DESMOPRESSIN MARKET SIZE, BY GERIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 308. CHINA DESMOPRESSIN MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 309. CHINA DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. CHINA DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 311. CHINA DESMOPRESSIN MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 312. CHINA DESMOPRESSIN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 313. CHINA DESMOPRESSIN MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
TABLE 314. CHINA DESMOPRESSIN MARKET SIZE, BY CHRONIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 315. CHINA DESMOPRESSIN MARKET SIZE, BY TRANSIENT DISORDERS, 2018-2030 (USD MILLION)
TABLE 316. INDIA DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 317. INDIA DESMOPRESSIN MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 318. INDIA DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 319. INDIA DESMOPRESSIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 320. INDIA DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 321. INDIA DESMOPRESSIN MARKET SIZE, BY BEDWETTING, 2018-2030 (USD MILLION)
TABLE 322. INDIA DESMOPRESSIN MARKET SIZE, BY DIABETES INSIPIDUS, 2018-2030 (USD MILLION)
TABLE 323. INDIA DESMOPRESSIN MARKET SIZE, BY NOCTURIA, 2018-2030 (USD MILLION)
TABLE 324. INDIA DESMOPRESSIN MARKET SIZE, BY SURGICAL USE, 2018-2030 (USD MILLION)
TABLE 325. INDIA DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 326. INDIA DESMOPRESSIN MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 327. INDIA DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 328. INDIA DESMOPRESSIN MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 329. INDIA DESMOPRESSIN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 330. INDIA DESMOPRESSIN MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 331. INDIA DESMOPRESSIN MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 332. INDIA DESMOPRESSIN MARKET SIZE, BY GERIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 333. INDIA DESMOPRESSIN MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 334. INDIA DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 335. INDIA DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 336. INDIA DESMOPRESSIN MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 337. INDIA DESMOPRESSIN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 338. INDIA DESMOPRESSIN MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
TABLE 339. INDIA DESMOPRESSIN MARKET SIZE, BY CHRONIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 340. INDIA DESMOPRESSIN MARKET SIZE, BY TRANSIENT DISORDERS, 2018-2030 (USD MILLION)
TABLE 341. INDONESIA DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 342. INDONESIA DESMOPRESSIN MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 343. INDONESIA DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 344. INDONESIA DESMOPRESSIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 345. INDONESIA DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 346. INDONESIA DESMOPRESSIN MARKET SIZE, BY BEDWETTING, 2018-2030 (USD MILLION)
TABLE 347. INDONESIA DESMOPRESSIN MARKET SIZE, BY DIABETES INSIPIDUS, 2018-2030 (USD MILLION)
TABLE 348. INDONESIA DESMOPRESSIN MARKET SIZE, BY NOCTURIA, 2018-2030 (USD MILLION)
TABLE 349. INDONESIA DESMOPRESSIN MARKET SIZE, BY SURGICAL USE, 2018-2030 (USD MILLION)
TABLE 350. INDONESIA DESMOPRESSIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 351. INDONESIA DESMOPRESSIN MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 352. INDONESIA DESMOPRESSIN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 353. INDONESIA DESMOPRESSIN MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 354. INDONESIA DESMOPRESSIN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 355. INDONESIA DESMOPRESSIN MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 356. INDONESIA DESMOPRESSIN MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 357. INDONESIA DESMOPRESSIN MARKET SIZE, BY GERIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 358. INDONESIA DESMOPRESSIN MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 359. INDONESIA DESMOPRESSIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 360. INDONESIA DESMOPRESSIN MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 361. INDONESIA DESMOPRESSIN MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 362. INDONESIA DESMOPRESSIN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 363. INDONESIA DESMOPRESSIN MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
TABLE 364. INDONESIA DESMOPRESSIN MARKET SIZE, BY CHRONIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 365. INDONESIA DESMOPRESSIN MARKET SIZE, BY TRANSIENT DISORDERS, 2018-2030 (USD MILLION)
TABLE 366. JAPAN DESMOPRESSIN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 367. JAPAN DESMOPRESSIN MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 368. JAPAN DESMOPRESSIN MARKET SIZE, BY INTRANASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 369. JAPAN DESMOPRESSIN MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 370. JAPAN DESMOPRESSIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 371. JAPAN DESMOPRESSIN MARKET SIZE, BY BEDWETTING, 2018-20

Companies Mentioned

  • AA Pharma Inc.
  • Amring Pharmaceuticals Inc.
  • Antares Pharma, Inc. by Halozyme, Inc.
  • Apotex Inc.
  • Avadel Pharmaceuticals PLC
  • Bachem AG
  • BluePoint Laboratories
  • CSC Pharmaceuticals International
  • Dr. Reddy's Laboratories Ltd.
  • Enomark
  • Ferring Pharmaceuticals
  • Glenmark Pharmaceuticals Limited
  • Horizon NJ Health by Horizon Blue Cross Blue Shield of New Jersey
  • KVR Pharmaceuticals
  • Manus Aktteva Biopharma LLP
  • Midas Pharma GmbH
  • NorthStar Rx LLC
  • Pfizer Inc.
  • Ralington Pharma LLP
  • Saintroy Lifescience
  • Sanofi S.A.
  • Sava Healthcare Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • VIVAN Life Sciences Pvt. Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Desmopressin - Global Strategic Business Report - Product Image

Desmopressin - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Desmopressin Market by Form, Sales Channel, End-Users - Global Forecast 2025-2030 - Product Image

Desmopressin Market by Form, Sales Channel, End-Users - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Desmopressin (DDAVP) Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Desmopressin (DDAVP) Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 96 Pages
  • Global
From
Antidiuretic Drugs - Global Strategic Business Report - Product Image

Antidiuretic Drugs - Global Strategic Business Report

  • Report
  • 178 Pages
  • Global
From
Enuresis Treatment Drug Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Enuresis Treatment Drug Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 114 Pages
  • Global
From

About the Market

Desmopressin is a synthetic analogue of the natural hormone arginine vasopressin, used to treat endocrine and metabolic disorders. It is used to treat diabetes insipidus, a condition in which the body does not produce enough antidiuretic hormone, resulting in excessive urination and dehydration. It is also used to treat nocturnal enuresis, or bedwetting, in children. Desmopressin is available in tablet, intranasal spray, and injection forms. Desmopressin is also used to treat von Willebrand disease, a bleeding disorder caused by a deficiency of von Willebrand factor. It is used to increase the level of von Willebrand factor in the blood, allowing it to clot more effectively. Desmopressin is a widely used drug in the endocrine and metabolic disorders market. It is available from many pharmaceutical companies, including Novartis, Pfizer, and Merck. It is also available in generic forms from many generic drug manufacturers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.